Virbac SA (VIRP) Fair Value & Analysis
Healthcare · FR · Market cap €3.0B
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 6 days ago
Share price −7.3% over the past month.
Price vs Fair Value (12 months)
12‑month range €310.27 – €387.46 · fair‑value band €193.39 – €495.06 · the €335.50 price screens above the €327.25 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Virbac SA (VIRP) currently trades at €335.50, while our model-based Fair Value estimate is €327.25 — implying the stock looks roughly 2.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Virbac SA generated revenue of €1.5B at a net margin of 10.3%. Revenue grew 4.6% year over year. It earns a return on equity of 13.9%. Net debt stands at €173M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Virbac SA reported revenue of €1.5B in FY2025 versus €1.1B in FY2021, a compound +8.3%/yr. Reported net income was €151M in FY2025, compounding +7.5%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| AstraZeneca PLC A1ZN34 | R$157.11 | R$108.37 | -31% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Virbac SA (VIRP) undervalued?
What is the fair value of VIRP?
What is the quality score of VIRP?
What is the revenue of Virbac SA (VIRP)?
What is the net profit margin of VIRP?
Does Virbac SA pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.